Ativan Lorazepam Withdrawal


If You Are Already in Ativan Lorazepam Withdrawal click here

How to Taper Ativan.
About James Harper
Member of National Association of Alcoholism and Drug Abuse Counselors
Member of Florida Association of Addiction Professionals
Expert DNA Witness (Los Angeles, CA. Courts)
Speaker/Presenter for CME at Medical Colleges

1. What is Ativan?

Ativan (lorazepam) was first approved by the U.S. Food and Drug Administration (FDA) in 1977. It is considered a short-to-intermediate acting benzodiazepine. Unlike some other benzodiazepines, lorazepam does not rely heavily on liver metabolism, making it more predictable in certain populations.

Ativan is classified as a Schedule IV controlled substance in the United States due to its potential for abuse and dependence.

2. How Does Ativan Work?

Ativan works by enhancing the activity of gamma-aminobutyric acid (GABA), a neurotransmitter in the brain that inhibits overactive nerve signaling. By amplifying GABA’s effects, Ativan produces:

  • Sedation
  • Muscle relaxation
  • Reduced anxiety
  • Anticonvulsant effects

This makes Ativan effective for anxiety, insomnia, seizures, and pre-surgical calming.

3. FDA-Approved Uses

Ativan has several official medical indications:

  • Anxiety disorders and short-term relief of anxiety symptoms
  • Preoperative sedation (before surgery or procedures)
  • Status epilepticus (severe, continuous seizure emergency – usually given intravenously)

4. Off-Label Uses

Physicians may also prescribe Ativan for off-label conditions, such as:

  • Panic disorder
  • Insomnia
  • Alcohol withdrawal
  • Chemotherapy-induced nausea and vomiting
  • Restlessness due to psychiatric disorders

5. Dosage and Administration

Ativan is available in tablets, oral solutions, and injectable forms.

  • Oral tablets: 0.5 mg, 1 mg, and 2 mg
  • Injectable: 2 mg/mL and 4 mg/mL solutions

Typical dosing:

  • Anxiety: 2–3 mg per day, divided into smaller doses.
  • Insomnia due to anxiety: 2–4 mg at bedtime.
  • Pre-surgical sedation: 0.05 mg/kg IM or IV, about 2 hours before procedure.
  • Status epilepticus: 4 mg IV at 2 mg/min, may repeat once after 10–15 minutes.

Important: Ativan is generally prescribed for short-term use only (2–4 weeks) to avoid dependence.

6. Common Side Effects

Patients taking Ativan may experience:

These side effects are typically dose-dependent and may lessen as the body adjusts.

7. Serious Side Effects

More dangerous reactions can occur, including:

Immediate medical attention is required if difficulty breathing, extreme drowsiness, or allergic reactions occur.

8. Interactions

Ativan can interact dangerously with other medications and substances:

  • Alcohol (increases sedation, risk of overdose)
  • Opioids (high risk of fatal respiratory depression)
  • Other sedatives or sleep medications
  • Antihistamines with sedating effects
  • Certain antidepressants and anticonvulsants

Because of these risks, Ativan should not be combined with alcohol or opioids unless specifically directed under medical supervision.

9. Ativan vs. Other Benzodiazepines

Ativan vs. Xanax (Alprazolam)

  • Xanax is shorter-acting and more associated with rapid relief but higher dependence risk.
  • Ativan lasts slightly longer and may be preferred for sedation before surgery.

Ativan vs. Valium (Diazepam)

  • Valium has a much longer half-life.
  • Ativan may be safer for older adults since it does not accumulate as much.

Ativan vs. Klonopin (Clonazepam)

  • Klonopin is longer-acting, making it better for ongoing anxiety or seizures.
  • Ativan is better for acute episodes.

10. Dependence and Withdrawal

One of the most critical aspects of Ativan use is its high potential for dependence. Even after a few weeks, the body may begin to adapt, leading to withdrawal symptoms if stopped abruptly.

Withdrawal symptoms include:

Tapering is essential. Doctors recommend gradually reducing the dose over weeks or months. Abrupt discontinuation can be life-threatening.

11. Special Considerations

  • Pregnancy and breastfeeding: Ativan crosses the placenta and appears in breast milk. It may cause sedation, withdrawal, or “floppy infant syndrome” in newborns.
  • Children: Generally not recommended except for seizure emergencies.
  • Older adults: Increased risk of falls, confusion, and memory problems.
  • Substance use history: People with a history of alcohol or drug abuse are at higher risk for Ativan misuse.

12. Effectiveness in Anxiety Treatment

Studies show Ativan can be effective for short-term anxiety relief, but due to risks of dependence, it is usually not recommended for long-term treatment. Many patients transition to SSRIs, SNRIs, or psychotherapy for ongoing management of anxiety disorders.

13. Lifestyle and Supportive Approaches

When Ativan is prescribed, combining it with lifestyle strategies can improve outcomes and reduce reliance on the drug.

  • Therapy (CBT, DBT, or exposure therapy) helps manage anxiety long-term.
  • Mindfulness and relaxation practices reduce stress naturally.
  • Exercise and physical activity release endorphins and support mental health.
  • Sleep hygiene can help reduce the need for sedative medications.

14. Pros and Cons of Ativan

Pros:

  • Rapid relief of anxiety and panic symptoms
  • Effective as a sedative before surgery
  • Useful in emergencies (status epilepticus)
  • Predictable pharmacology

Cons:

  • High risk of dependence and withdrawal
  • Sedation and memory impairment
  • Dangerous interactions with alcohol and opioids
  • Not recommended for long-term use

15. Patient Experiences

Patients report mixed outcomes with Ativan:

  • Many describe it as “life-saving” for panic attacks and insomnia.
  • Others experience significant sedation and difficulty concentrating.
  • Dependence is a common theme — patients often struggle with tapering after months or years of use.

16. Long-Term Use Considerations

While Ativan can be effective short-term, long-term daily use is generally discouraged. Risks include:

  • Tolerance (needing higher doses for the same effect)
  • Physical and psychological dependence
  • Cognitive impairment
  • Higher risk of dementia with prolonged use (under study)

More About Ativan

Ativan (lorazepam) is a powerful benzodiazepine that plays an important role in treating anxiety, seizures, and preoperative sedation. Its rapid effectiveness makes it valuable in acute situations, but its high potential for dependence and withdrawal makes it unsuitable for long-term daily use.

Patients prescribed Ativan should work closely with their healthcare providers to ensure safe use, avoid dangerous interactions, and plan for tapering if long-term treatment is required.

With careful management, Ativan can be a useful short-term tool in managing anxiety and related conditions.

References

1, Comparison of the actions of diazepam and lorazepam

Diazepam and lorazepam differ in potency and in the time-course of their action. As a sedative, diazepam 10 mg is equivalent to lorazepam 2-2.5 mg. Diazepam is better absorbed after oral than after i.m. administrations but this does not apply to lorazepam. The clinical effect and amnesia begin more rapidly with diazepam, but last longer following lorazepam. Lorazepam is more effective than diazepam in blocking the emergence sequelae from ketamine. Lorazepam i.v. is followed by a lesser frequency of venous thrombosis.

2, The effects of benzodiazepines on cognition

Initially thought to be virtually free of negative effects, benzodiazepines are now known to carry risks of dependence, withdrawal, and negative side effects. Among the most controversial of these side effects are cognitive effects. Long-term treatment with benzodiazepines has been described as causing impairment in several cognitive domains, such as visuospatial ability, speed of processing, and verbal learning. Conversely, long-term benzodiazepine use has also been described as causing no chronic cognitive impairment, with any cognitive dysfunction in patients ascribed to sedation or inattention or considered temporary and associated with peak plasma levels. Complicating the issue are whether anxiety disorders themselves are associated with cognitive deficits and the extent to which patients are aware of their own cognitive problems. In an attempt to settle this debate, meta-analyses of peer-reviewed studies were conducted and found that cognitive dysfunction did in fact occur in patients treated long term with benzodiazepines, and although cognitive dysfunction improved after benzodiazepines were withdrawn, patients did not return to levels of functioning that matched benzodiazepine-free controls. Neuroimaging studies have found transient changes in the brain after benzodiazepine administration but no brain abnormalities in patients treated long term with benzodiazepines. Such findings suggest that patients should be advised of potential cognitive effects when treated long term with benzodiazepines, although they should also be informed that the impact of such effects may be insignificant in the daily functioning of most patients.

3, Lorazepam-efficacy, side effects, and rebound phenomena

Lorazepam, 4 mg, was evaluated in an 18-night sleep-laboratory study involving five insomniac subjects. Hypnotic effectiveness and effects on sleep stages and related parameters were assessed. Placebo was given on baseline nights 1 to 4, lorazepam on nights 5 to 11, and placebo was given again on withdrawal nights 12 to 18. Subjective and objective data clearly demonstrated that lorazepam was effective for both inducing and maintaining sleep. Sleep latency was reduced from a baseline value of 34.6 min to 17.9 min (P less than 0.01) and total wake time was reduced from 75.9 to 38.5 min (P less than 0.01). On the third and fifth nights of drug withdrawal total wake time rose above baseline levels (termed rebound insomnia) and sleep latency increased by 77% and 60% over baseline (P less than 0.01). Subjective estimates of daytime anxiety also increased above baseline (rebound anxiety) during the withdrawal period. All subjects experienced severe hangover and varying degrees of impaired functioning during the first 3 days on drug. Three subjects also experienced anterograde amnesia during the day after the first drug night. These side effects diminished in intensity over the course of the study. Our results suggest that while 4 mg lorazepam may be effective in inducing and maintaining sleep, this dose induces clinically significant side effects that are followed by consistent rebound phenomena after withdrawal.]

4. Effects of lorazepam on prosaccades and saccadic adaptation

Background: Benzodiazepines have reliable adverse effects on saccadic eye movements, but the impact of sex as a potential modulator of these effects is less clear. A recent study reported stronger adverse effects on the spatial consistency of saccades in females, which may reflect sex differences in cerebellar mechanisms.

Aims: We aimed to further examine the role of sex as a potential modulator of benzodiazepine effects by employing the saccadic adaptation paradigm, which is known to be sensitive to cerebellar functioning.

Methods: A total of n=50 healthy adults performed a horizontal step prosaccade task and a saccadic adaptation task under 0.5 mg lorazepam, 1 mg lorazepam and placebo in a double-blind, within-subjects design.

Results: In the prosaccade task, lorazepam had adverse effects on measures of peak velocity, latency and spatial consistency. The administration of 0.5 mg lorazepam led to significant reductions in gain-decrease adaptation, while a dose of 1 mg did not impair adaptation learning. Gain-increase adaptation was generally less pronounced, and unaffected by the drug. There were no significant drug×sex interactions in either task.

Conclusions: We conclude that a low dose of lorazepam impairs gain-decrease adaptation independent of sex. At higher doses, however, increasing fatigue may facilitate adaptation and thus counteract the adverse effects observed at lower doses. With regards to prosaccades, our findings confirm peak velocity as well as latency and spatial measures as sensitive biomarkers of GABAergic effects.

5. Effects of Intramuscular Midazolam and Lorazepam on Acute Agitation in Non-Elderly Subjects – A Systematic Review

Benzodiazepines are commonly used for the treatment of acute agitation in a psychiatric setting.We searched MEDLINE, EMBASE, PsycINFO, and the Cochrane Central Register of Controlled Trials (CENTRAL) for relevant publications. Randomized trials evaluating intramuscular (IM) midazolam or lorazepam given as monotherapy or as add-on treatment, with more than 10 patients aged 18-65 years, conducted in a psychiatric setting, and published between January 1, 1980, and February 3, 2016, were included. 16 studies from a search result of 5 516 studies were included. In total, 577 patients were treated with lorazepam IM 2-4 mg, and 329 patients were treated with midazolam IM 5-15 mg. It is unclear whether lorazepam IM or midazolam IM is as efficacious as an antipsychotic IM. It is a bit more certain that the combination of benzodiazepines IM and a low dose antipsychotic IM is more efficacious than the benzodiazepine and the antipsychotic alone. However, there is no doubt that benzodiazepines are less likely to be associated with treatment emergent side effects, as compared to antipsychotics.

6. Lorazepam-induced diplopia

Diplopia – seeing double – is a symptom with many potential causes, both neurological and ophthalmological. Benzodiazepine induced ocular side-effects are rarely reported. Lorazepam is one of the commonly used benzodiazepine in psychiatric practice. Visual problems associated with administration of lorazepam are rarely reported and the frequency of occurrence is not established. We report a rare case of lorazepam-induced diplopia in a newly diagnosed case of obsessive compulsive disorder.

7. Acute lorazepam effects on neurocognitive performance

A double-blind, placebo-controlled, crossover design was employed to determine whether acute lorazepam (2 mg orally) cognitive side effects would emerge in a differential age-dependent fashion in 15 young (mean age=22 years) and 12 older (mean age=64 years) subjects. Acute use of lorazepam is frequently the initial treatment choice for convulsive status epilepticus or repetitive seizure clusters. Cognitive assessment was performed during drug and placebo conditions using a computerized battery of cognitive tests. With the exception of performance on the reasoning composite score, significant drug effects were present on all primary cognitive domain measures. However, the only significant drug-by-age interaction effect was seen for dual-task performance. The relationship between test performance and plasma lorazepam concentrations was generally modest and non-significant, suggesting that individual differences in pharmacokinetics are not a major factor contributing to the emergence of cognitive side effects. Despite robust lorazepam effects on multiple measures of neurocognitive function, differential age effects are largely restricted to dual-task performance. These results indicate that with the exception of dual-task performance, older individuals in the age range of this study do not appear to be at increased risk for the emergence of cognitive side effects following a single 2-mg dose of lorazepam.

8. Efficacy and side effects of lorazepam, oxazepam, and temazepam as sleeping aids in psychogeriatric inpatients

The efficacy and side effects of 2 mg of lorazepam, 30 mg of oxazepam, and 20 mg of temazepam as sleeping aids were investigated in 20 psychogeriatric inpatients. The drugs were administered in a random order, double-blind, for 7 night each. All of these short half-life benzodiazepines proved efficacious in maintaining sleep. None of them reduced initial sleep latency. Oxazepam and to a lesser degree temazepam induced withdrawal insomnia during the first night after the treatments. The withdrawal of lorazepam induced a delayed but prolonged insomnia in 3 patients. Both lorazepam and oxazepam had muscle relaxant side effects after awakening.

9. Effects of lorazepam on saccadic eye movements: the role of sex, task characteristics and baseline traits

Background: Saccadic eye movements are controlled by a network of parietal, frontal, striatal, cerebellar and brainstem regions. The saccadic peak velocity is an established biomarker of benzodiazepine effects, with benzodiazepines reliably reducing the peak velocity.

Aims: In this study, we aimed to replicate the effects of benzodiazepines on peak velocity and we investigated effects on previously less studied measures of saccades. We also explored the roles of sex, task characteristics and the baseline variables age, intelligence and trait anxiety in these effects.

Method: Healthy adults ( N = 34) performed a horizontal step prosaccade task under 1 mg lorazepam, 2 mg lorazepam and placebo in a double-blind, within-subjects design.

Results: We replicated the dose-dependent reduction in peak velocity with lorazepam and showed that this effect is stronger for saccades to targets at smaller eccentricities. We also demonstrated that this effect is independent of sex and other baseline variables. Lorazepam effects were widespread, however, occurring on mean and variability measures of most saccadic variables. Additionally, there were sex-dependent lorazepam effects on spatial consistency of saccades, indicating more adverse effects in females.

Conclusions: We conclude that saccadic peak velocity is a sensitive and robust biomarker of benzodiazepine effects. However, lorazepam has pronounced effects also on other parameters of horizontal saccades. Sex-dependent drug effects on spatial consistency may reflect cerebellar mechanisms, given the role of the cerebellum in saccadic spatial accuracy.

10. Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability

The effects of orally administered placebo, diphenhydramine, lorazepam, methocarbamol and placebo were studied in volunteers with histories of recreational substance abuse including sedative/hypnotics. Placebo, diphenhydramine (100, 200 and 400 mg), lorazepam (1 and 4 mg) and methocarbamol (2.25 and 9 g) were tested in a randomized, double-blind crossover study using 14 subjects. Psychomotor and cognitive performance and subject- and observer-rated responses were measured daily before and for 5.5 hr after drug administration. The results showed that each of the drugs exhibited a different profile of effects on the test battery. Lorazepam produced significant increases in subjects’ ratings of drug effect and liking, increases in measures of sedation and impairment of psychomotor performance. Methocarbamol also produced significant increases in subjects’ ratings of drug effect and liking and measures of sedation, but it produced only minor impairment of psychomotor and cognitive performance. Diphenhydramine increased subjects’ and observers’ ratings of drug effect and measures of sedation, but it produced less psychomotor performance impairment and liking than lorazepam. Diphenhydramine produced the most side effects. The present study clearly differentiated the behavioral and subjective profiles of diphenhydramine, lorazepam and methocarbamol. Consistent with its recognized low abuse liability, diphenhydramine produced fewer increases in measures of positive mood and more adverse effects. The considerable overlap in subjective effect measures of positive mood make further differentiation with respect to abuse liability difficult.